Systematic Study on Genetic and Epimutational Profile of a Cohort of Amsterdam Criteria-defined Lynch Syndrome in Singapore

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Apr 9

PMID 24710284

Citations 4

Authors

Yanqun Liu

Min Hoe Chew

Xue Wei Goh

Soo Yong Tan

Carol Tien Tau Loi

Yuen Ming Tan

Hai Yang Law

Poh Koon Koh

Choong Leong Tang

Affiliations

Soon will be listed here.

Abstract

Background: Germline defects of mismatch repair (MMR) genes underlie Lynch Syndrome (LS). We aimed to gain comprehensive genetic and epigenetic profiles of LS families in Singapore, which will facilitate efficient molecular diagnosis of LS in Singapore and the region.

Methods: Fifty nine unrelated families were studied. Mutations in exons, splice-site junctions and promoters of five MMR genes were scanned by high resolution melting assay followed by DNA sequencing, large fragment deletions/duplications and promoter methylation in MLH1, MSH2, MSH6 and PMS2 were evaluated by multiplex ligation-dependent probe amplification. Tumor microsatellite instability (MSI) was assessed with five mononucleotide markers and immunohistochemical staining (IHC) was also performed.

Results: Pathogenic defects, all confined to MLH1 and MSH2, were identified in 17 out of 59 (28.8%) families. The mutational spectrum was highly heterogeneous and 28 novel variants were identified. One recurrent mutation in MLH1 (c.793C>T) was also observed. 92.9% sensitivity for indication of germline mutations conferred by IHC surpassed 64.3% sensitivity by MSI. Furthermore, 15.6% patients with MSS tumors harbored pathogenic mutations.

Conclusions: Among major ethnic groups in Singapore, all pathogenic germline defects were confined to MLH1 and MSH2. Caution should be applied when the Amsterdam criteria and consensus microsatellite marker panel recommended in the revised Bethesda guidelines are applied to the local context. We recommend a screening strategy for the local LS by starting with tumor IHC and the hotspot mutation testing at MLH1 c.793C>T followed by comprehensive mutation scanning in MLH1 and MSH2 prior to proceeding to other MMR genes.

Citing Articles

Identification of Lynch Syndrome in Patients with Endometrial Cancer Based on a Germline Next Generation Sequencing Multigene Panel Test.

Kim Y, Kim M, Lee Y, Lee Y, Sohn J, Lee J Cancers (Basel). 2022; 14(14).

PMID: 35884469 PMC: 9316192. DOI: 10.3390/cancers14143406.

Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results.

Olkinuora A, Gylling A, Almusa H, Eldfors S, Lepisto A, Mecklin J Cancers (Basel). 2020; 12(7).

PMID: 32660107 PMC: 7408769. DOI: 10.3390/cancers12071853.

Identification of novel Lynch syndrome mutations in Chinese patients with endometriod endometrial cancer.

Ren C, Liu Y, Wang Y, Tang Y, Wei Y, Liu C Cancer Biol Med. 2020; 17(2):458-467.

PMID: 32587781 PMC: 7309470. DOI: 10.20892/j.issn.2095-3941.2019.0295.

Prevalence and spectrum of , , and pathogenic germline variants in Pakistani colorectal cancer patients.

Rashid M, Naeemi H, Muhammad N, Loya A, Lubinski J, Jakubowska A Hered Cancer Clin Pract. 2019; 17:29.

PMID: 31660093 PMC: 6806584. DOI: 10.1186/s13053-019-0128-2.

References

Chew M, Koh P, Ng K, Lim J, Ho K, Ooi B . Phenotypic characteristics of hereditary non-polyposis colorectal cancer by the Amsterdam criteria: an Asian perspective. ANZ J Surg. 2008; 78(7):556-60. DOI: 10.1111/j.1445-2197.2008.04570.x. View

Di Fiore F, Charbonnier F, Martin C, Frerot S, Olschwang S, Wang Q . Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet. 2004; 41(1):18-20. PMC: 1757274. DOI: 10.1136/jmg.2003.012062. View

Plaschke J, Ruschoff J, Schackert H . Genomic rearrangements of hMSH6 contribute to the genetic predisposition in suspected hereditary non-polyposis colorectal cancer syndrome. J Med Genet. 2003; 40(8):597-600. PMC: 1735570. DOI: 10.1136/jmg.40.8.597. View

Vasen H, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I . Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6):353-62. PMC: 2740877. DOI: 10.1136/jmg.2007.048991. View

Wang X, Yuan Y, Zhang S, Cai S, Huang Y, Jiang Q . Clinical and genetic characteristics of Chinese hereditary nonpolyposis colorectal cancer families. World J Gastroenterol. 2006; 12(25):4074-7. PMC: 4087725. DOI: 10.3748/wjg.v12.i25.4074. View

Vasen H, Mecklin J, Khan P, Lynch H . The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991; 34(5):424-5. DOI: 10.1007/BF02053699. View

Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French A . BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004; 41(9):664-8. PMC: 1735885. DOI: 10.1136/jmg.2004.020651. View

Bessa X, Belen Balleste , Andreu M, Castells A, Bellosillo B, Balaguer F . A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol. 2007; 6(2):206-14. DOI: 10.1016/j.cgh.2007.10.011. View

Bonis P, Trikalinos T, Chung M, Chew P, Ip S, Devine D . Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep). 2007; (150):1-180. PMC: 4781224. View

10.

Ellegren H . Microsatellites: simple sequences with complex evolution. Nat Rev Genet. 2004; 5(6):435-45. DOI: 10.1038/nrg1348. View

11.

Liu Y, Zhao Y, Wu C, Ho K, Koh P, Fook Chong S . Modest promoter methylation of E-cadherin gene in sporadic colorectal cancers: a quantitative analysis. Cancer Biomark. 2008; 4(2):111-20. DOI: 10.3233/cbm-2008-4207. View

12.

Tang R, Hsiung C, Wang J, Lai C, Chien H, Chiu L . Germ line MLH1 and MSH2 mutations in Taiwanese Lynch syndrome families: characterization of a founder genomic mutation in the MLH1 gene. Clin Genet. 2009; 75(4):334-45. DOI: 10.1111/j.1399-0004.2009.01162.x. View

13.

Nakahara M, Yokozaki H, Yasui W, Dohi K, Tahara E . Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds. Cancer Epidemiol Biomarkers Prev. 1998; 6(12):1057-64. View

14.

Jensen L, Lindebjerg J, Byriel L, Kolvraa S, Cruger D . Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis. 2007; 10(5):490-7. DOI: 10.1111/j.1463-1318.2007.01378.x. View

15.

Wagner A, Barrows A, Wijnen J, Van der Klift H, Franken P, Verkuijlen P . Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet. 2003; 72(5):1088-100. PMC: 1180263. DOI: 10.1086/373963. View

16.

Suter C, Martin D, Ward R . Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004; 36(5):497-501. DOI: 10.1038/ng1342. View

17.

Joensuu E, Abdel-Rahman W, Ollikainen M, Ruosaari S, Knuutila S, Peltomaki P . Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res. 2008; 68(12):4597-605. DOI: 10.1158/0008-5472.CAN-07-6645. View

18.

Chan T, Chan Y, Ho J, Chan C, Chan A, Chan E . MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population. Am J Hum Genet. 2004; 74(5):1035-42. PMC: 1181966. DOI: 10.1086/383591. View

19.

Peltomaki P, Vasen H . Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004; 20(4-5):269-76. PMC: 3839397. DOI: 10.1155/2004/305058. View

20.

Wei W, Liu L, Chen J, Jin K, Jiang F, Liu F . Racial differences in MLH1 and MSH2 mutation: an analysis of yellow race and white race based on the InSiGHT database. J Bioinform Comput Biol. 2010; 8 Suppl 1:111-25. DOI: 10.1142/s0219720010005154. View